Based on the results of our data collection, we found that weight-based dosing with enoxaparin 0.5 mg/kg in morbidly obese, critically ill patients was effective in achieving anti-factor Xa levels ...
RESULTS: A weight-based dosage range of enoxaparin 50 ... The mean BMI was 46.4 kg/m2. The initial mean anti-factor Xa level (measured after the third dose) was 0.34 IU/mL (range 0.20–0. ...
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results ...
Adjusted EPS grew to $0.92, a 4.5% rise over the previous year ... Epinephrine sales fell by 24% due to heightened competition, and Enoxaparin revenues dropped 39% amid market shifts.
Principal Financial Group Inc. increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the ...
Smartleaf Asset Management LLC grew its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 222 ...
While the mutation was linked to these miscarriages, results found that administering folic acid alongside low dose aspirin and enoxaparin was ... contains at least 0.4 milligrams (mg) of folic ...
The Jordan 4 has been arguably the hottest retro design from the iconic brand in 2025. With the release of the Abundance and ...
For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results